Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*
British Journal of Dermatology2020Vol. 184(1), pp. 133–140
Citations Over TimeTop 1% of 2020 papers
Angelo Valerio Marzano, Giovanni Genovese, Giovanni Casazza, Chiara Moltrasio, Paolo Dapavo, Giuseppe Micali, Riccardo Sirna, Paolo Gisondi, Annalisa Patrizi, Valentina Dini, Daniela Bianchini, Luca Bianchi, Luca Fania, Francesca Prignano, Annamaria Offidani, Laura Atzori, Vincenzo Bettoli, Salvatore Cannavò, Marina Venturini, Maria Rita Bongiorno, Antonio Costanzo, Gabriella Fabbrocini, Ketty Peris
Abstract
Inverse correlation between therapeutic delay and clinical response was found, supporting early adalimumab use and providing evidence for a 'window of opportunity' in HS treatment. Adalimumab efficacy and safety were confirmed, along with patients' QoL improvement. Immunosuppressants could negatively influence the response to adalimumab inducing a switch to non-TNF-α-driven pathways.
Related Papers
- → Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting(2023)47 cited
- → Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data(2018)34 cited
- → Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab(2019)22 cited
- → A note on improvement in dermatology life quality index (DLQI) among patients with hidradenitis suppurativa treated with adalimumab(2018)4 cited
- → Employing Adalimumab in Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Real‐Life Multicenter Data from the Czech Republic(2023)1 cited